Literature DB >> 2971321

Thymoxamine reverses phenylephrine-induced mydriasis.

S J Relf1, N Z Gharagozloo, G L Skuta, W L Alward, D R Anderson, R F Brubaker.   

Abstract

We performed a randomized double-masked evaluation of the alpha-adrenergic blocking agent thymoxamine (0.1%) as compared to placebo for the reversal of phenylephrine-induced mydriasis. Topically applied thymoxamine reversed the mydriasis from a single drop of 2.5% phenylephrine in 36 of 40 eyes (90%) within one hour. The mydriasis was completely reversed in 25 of 40 eyes (63%). Eyes with blue irides responded more quickly and more completely than did those with brown irides. The 40 contralateral eyes, which had also been dilated with phenylephrine, remained dilated or dilated further after receiving a placebo eyedrop. Twenty subjects (50%) reported mild transient ocular irritation upon instillation of thymoxamine. Thymoxamine was useful in individuals with narrow anterior chamber angles who were at risk of acute closed-angle glaucoma following dilation with an adrenergic agent.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971321     DOI: 10.1016/0002-9394(88)90356-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

1.  Evaluation of alpha1-adrenoceptors in the rabbit iris: pharmacological characterization and expression of mRNA.

Authors:  S Nakamura; T Taniguchi; F Suzuki; Y Akagi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Evaluation of the effect of thymoxamine solution 0.5% on mydriasis induced by ibopamine solution 1%.

Authors:  F Drago; A Dal Bello; V Marino; R Pisati; E Lodola; P Barbieri
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Severe anisocoria after oral surgery under general anesthesia.

Authors:  Francesco Inchingolo; Marco Tatullo; Fabio M Abenavoli; Massimo Marrelli; Alessio D Inchingolo; Bruno Villabruna; Angelo M Inchingolo; Gianna Dipalma
Journal:  Int J Med Sci       Date:  2010-09-10       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.